Log in
(Ad)
And Reuters magazine calls this type of trading "the new baby boomer hobby." An anonymous trader -- living at the base of the Smoky Mountains -- just released a free report revealing a step-by-step system to generating an extra $5,000 per month in income thanks to this trading strategy. The report is free until Sunday.

NASDAQ:TECH - BIO-TECHNE Stock Price, Forecast & News

$220.61
+1.20 (+0.55 %)
(As of 01/19/2020 04:00 PM ET)
Today's Range
$218.00
Now: $220.61
$221.34
50-Day Range
$212.87
MA: $217.98
$222.09
52-Week Range
$159.08
Now: $220.61
$223.28
Volume208,552 shs
Average Volume110,308 shs
Market Capitalization$8.41 billion
P/E Ratio92.31
Dividend Yield0.58%
Beta1.22
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$714.01 million
Cash Flow$6.00 per share
Book Value$30.78 per share

Profitability

Net Income$96.07 million

Miscellaneous

Employees2,250
Market Cap$8.41 billion
Next Earnings Date2/4/2020 (Confirmed)
OptionableOptionable

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Want to know which stocks should be on your radar this week? Every Sunday we send out the 3 Stock Trades that we predict will be big winners for the week ahead.

BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions

What is BIO-TECHNE's stock symbol?

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?

BIO-TECHNE declared a quarterly dividend on Tuesday, October 29th. Stockholders of record on Friday, November 8th will be given a dividend of $0.32 per share on Friday, November 22nd. This represents a $1.28 annualized dividend and a dividend yield of 0.58%. The ex-dividend date is Thursday, November 7th. View BIO-TECHNE's Dividend History.

How were BIO-TECHNE's earnings last quarter?

BIO-TECHNE Corp (NASDAQ:TECH) posted its earnings results on Tuesday, October, 29th. The biotechnology company reported $1.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.92 by $0.14. The biotechnology company earned $183.24 million during the quarter, compared to the consensus estimate of $179.38 million. BIO-TECHNE had a return on equity of 13.36% and a net margin of 12.68%. The firm's quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.98 earnings per share. View BIO-TECHNE's Earnings History.

When is BIO-TECHNE's next earnings date?

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for BIO-TECHNE.

How can I listen to BIO-TECHNE's earnings call?

BIO-TECHNE will be holding an earnings conference call on Tuesday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for TECH?

8 brokers have issued 12 month target prices for BIO-TECHNE's shares. Their forecasts range from $179.00 to $270.00. On average, they anticipate BIO-TECHNE's stock price to reach $231.50 in the next year. This suggests a possible upside of 4.9% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

What is the consensus analysts' recommendation for BIO-TECHNE?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

Has BIO-TECHNE been receiving favorable news coverage?

News headlines about TECH stock have been trending positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BIO-TECHNE earned a news impact score of 3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for BIO-TECHNE.

Are investors shorting BIO-TECHNE?

BIO-TECHNE saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 418,000 shares, an increase of 12.7% from the December 15th total of 370,900 shares. Based on an average daily trading volume, of 121,200 shares, the short-interest ratio is currently 3.4 days. Currently, 1.1% of the company's shares are short sold. View BIO-TECHNE's Current Options Chain.

Who are some of BIO-TECHNE's key competitors?

What other stocks do shareholders of BIO-TECHNE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), AbbVie (ABBV), Global Medical REIT (GMRE), Amgen (AMGN), Gilead Sciences (GILD), NVIDIA (NVDA), General Electric (GE), Crispr Therapeutics (CRSP), Cisco Systems (CSCO) and Ionis Pharmaceuticals (IONS).

Who are BIO-TECHNE's key executives?

BIO-TECHNE's management team includes the folowing people:
  • Mr. Charles R. Kummeth, CEO, Pres & Director (Age 59)
  • Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 48)
  • Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 61)
  • Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 58)
  • Mr. Gerry Andros, VP of Sales and Marketing

Who are BIO-TECHNE's major shareholders?

BIO-TECHNE's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (1.02%), Summit Creek Advisors LLC (0.22%), Nisa Investment Advisors LLC (0.05%), Assenagon Asset Management S.A. (0.04%), Tributary Capital Management LLC (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View Institutional Ownership Trends for BIO-TECHNE.

Which institutional investors are selling BIO-TECHNE stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, State of Alaska Department of Revenue, Tributary Capital Management LLC, Summit Creek Advisors LLC and We Are One Seven LLC. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor and Roeland Nusse. View Insider Buying and Selling for BIO-TECHNE.

Which institutional investors are buying BIO-TECHNE stock?

TECH stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Tocqueville Asset Management L.P., Chicago Capital LLC, First National Bank of Omaha, Nisa Investment Advisors LLC, Diversified Trust Co, Huntington National Bank and Argus Investors Counsel Inc.. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

How do I buy shares of BIO-TECHNE?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIO-TECHNE's stock price today?

One share of TECH stock can currently be purchased for approximately $220.61.

How big of a company is BIO-TECHNE?

BIO-TECHNE has a market capitalization of $8.41 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

What is BIO-TECHNE's official website?

The official website for BIO-TECHNE is http://www.techne-corp.com/.

How can I contact BIO-TECHNE?

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]


MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  306 (Vote Outperform)
Underperform Votes:  334 (Vote Underperform)
Total Votes:  640
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: FinTech

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel